Ikaria Holdings, Inc., (Seattle, USA) is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations for the critically ill. The company's product, INOmax (nitric oxide) for inhalation, is an FDAapproved drug for the treatment of hypoxic respiratory failure in term and near-term newborns.

In addition to marketing and selling its INOmax product, Ikaria is engaged in both Phase II trials with Covox (carbon monoxide) for inhalation and Phase I trials with hydrogen sulfide (H2S: induction of reversible metabolic hibernation) for various indications.